SCHEMBL21773285

SCHEMBL21773285

COc1ccc(CN(c2cscn2)S(=O)(=O)c2cc(C)c(NC3C[C@H]4CC[C@@H](C3)N4C(=O)O)cn2)cc1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 8/20 0.36
LTA4H P09960 1/20 0.35
MMP1 P03956 8/20 0.34
MMP13 P45452 8/20 0.34
ADAM17 P78536 2/20 0.34
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
TYK2 P29597 1/20 0.34
JAK3 P52333 1/20 0.34
MMP12 P39900 1/20 0.33
SCN1A P35498 3/20 0.33
SCN8A Q9UQD0 3/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
ALDH1A1 P00352 1/20 0.33
KEAP1 Q14145 1/20 0.33
NFE2L2 Q16236 1/20 0.33
TRPM8 Q7Z2W7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21773278 1.00 MMP9 (0.36) MMP9LTA4HMMP1MMP13ADAM17
SCHEMBL21773280 1.00 MMP9 (0.36) MMP9LTA4HMMP1MMP13ADAM17
SCHEMBL21789254 0.91 GPR119 (0.38) ALDH1A1
SCHEMBL30845658 0.91 GPR119 (0.38) ALDH1A1
SCHEMBL30845712 0.91 GPR119 (0.38) ALDH1A1
SCHEMBL21773210 0.87 SCN1A (0.39) MMP9MMP1MMP13ADAM17SCN1A
SCHEMBL21773213 0.87 SCN1A (0.39) MMP9MMP1MMP13ADAM17SCN1A
SCHEMBL21773268 0.86 SCN8A (0.42) MMP9MMP12SCN1ASCN8AKEAP1
SCHEMBL21773267 0.86 SCN8A (0.42) MMP9MMP12SCN1ASCN8AKEAP1
SCHEMBL21773271 0.86 SCN8A (0.42) MMP9MMP12SCN1ASCN8AKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752623-B2 Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors XENON PHARMACEUTICALS INC. (CA) 2020-08-25 US disclosed
US-20200071313-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2020-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071313-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS SCN1A, SCN2A, SCN2B MMP9 2673/4885LTA4H 2237/4885MMP1 4254/4885
US-10752623-B2 Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors SCN1A, SCN2A, SCN2B MMP9 2673/4885LTA4H 2237/4885MMP1 4254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.